Background/Introduction
Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) treated non-surgically. Meta-analyses show an improved 5-year survival by approximately 8% when CCRT is compared to radiotherapy alone 1, 2 . The advantage of this approach with respect to disease free survival and local-regional control is greater than 8% [3] [4] [5] [6] [7] [8] [9] [10] .
While there are undisputed advantages to CCRT for local-regional control, it increases toxicity when compared to radiotherapy alone 11 . Many studies have focused on acute toxicity, particularly mucositis, as summarized in a meta-analysis by Trotti et al. 12 .
Comprehensive data on late toxicity from randomized trials of RT +/-chemotherapy, however, are sparse. Late toxicity may include long-term severe dysphagia and its related effects, including dependence upon a feeding tube, and have a profound effect on quality of life. The increased incidence of these serious, potentially permanent effects after CCRT is concerning, leading some to question as to whether chemoradiotherapy is truly a major improvement in the therapeutic ratio over radiotherapy alone. 13 Starting approximately 15 years ago, the RTOG conducted a series of prospective clinical trials using CCRT for locally advanced SCCHN. General data on efficacy and early and subacute toxicity have been reported [14] [15] [16] . It is likely, however, that each individual study is underpowered for a thorough analysis of late effects, given sample size and patient attrition due to mortality and other causes. Consequently, we performed a secondary analysis of severe late toxicities from these several trials, specifically focusing on late toxicities and mortality related to pharyngolaryngeal dysfunction. An analysis of potential factors associated with severe late toxicities was undertaken.
Materials/Methods
As noted above, the three prospective trials analyzed for this paper have been previously reported. All three studies required an acceptable performance status (60-100% by Karnofsky scale); non-metastatic stage III/IV SCCHN; and good hematologic, renal, hepatic and cardiovascular function.
Briefly, the three studies are:
RTOG 91-11 14 : A phase III trial of larynxpreserving radiotherapy or chemoradiotherapy for selected Stage III/IV larynx cancer. For this analysis, only the concurrent chemoradiotherapy arm was studied; this treatment in this arm consisted of 70 Gy in conventionally fractionated radiotherapy (XRT) -2 Gy once daily -plus three cycles of high dose Machtay, M. et al: J. Clin. Oncol. 26 (21), 2008:3582-3589. RTOG Analysis cisplatin (100 mg/m2, Weeks 1, 4, and 7). There were 172 patients in this arm from RTOG 91-11; 88 patients were evaluable for this analysis of late toxicity.
RTOG 97-03
17 : A Phase IIR trial of several novel regimens of concurrent chemoradiotherapy for stage III/IV head and neck cancer (excluding patients who were eligibile for RTOG 91-11). This study included three arms. Arms 1 and 3 utilized conventionally fractionated XRT as per 91-11. Arm 1 chemotherapy was infusional 5-FU and cisplatin, both given daily during the last two weeks of XRT. Arm 3 chemotherapy was once weekly cisplatin (20 mg/m2/week) and paclitaxel (30 mg/m2/week). Arm 2 chemoradiotherapy was modeled upon the prospective phase II trials performed by the University of Chicago. In Arm 2, although the total XRT dose remained 70 Gy in 2 Gy fractions, it was delivered over 13 weeks (week-on, week-off technique); chemotherapy in Arm 2 consisted of concurrent infusional 5-FU and hydroxyurea. There were 231 patients in RTOG 97-03; 102 patients were evaluable for this analysis of late toxicity.
RTOG 99-14 16 : A Phase II trial of accelerated radiotherapy with concurrent chemotherapy for stage III/IV head and neck cancer. This single arm phase II study consisted of accelerated concomitant boost radiotherapy to 72 Gy over 6 weeks (as per the concomitant boost arm of RTOG 90-03), with two cycles of high dose cisplatin (100 mg/m2 weeks 1 and 4). There were 76 patients in RTOG 99-14; 40 patients were evaluable for this analysis of late toxicity.
All of these studies used conventional radiotherapy techniques, mostly 2-dimensional planning and delivery. No patient received intensity modulated radiation therapy (IMRT). For this report, a severe late toxicity was defined as any or all of the following events:
• Grade 3 or greater toxicity (RTOG/EORTC Late Toxicity Criteria) present > 180 days after the start of XRT and clearly related to dysfunction of the larynx and/or pharynx (e.g. dysphagia)
• Requirement for a feeding tube/gastrostomy 2 years or longer after the start of XRT.
• Death without cancer progression and from an uncertain cause in which laryngeal dysfunction is suspected to be a contributing factor (e.g. pneumonia) ≤ 3 years from the date of randomization. Patients who died of unknown causes were included in this category. Review of these deaths was performed by one of the study authors (MM) in a manner blinded to any of the patient's clinical pre-treatment and/or treatment related characteristics.
Patients who suffered one or more qualifying severe late toxicity events were only considered to be one "case. "
Patients with severe laryngopharynx dysfunction due to cancer, prior to the start of treatment, were excluded because of the potential confounding nature of tumor destruction of critical normal tissues (See Table 1 ). In RTOG 91-11, the determination of severe pre-treatment laryngopharynx dysfunction was based on patients' on-study data collection form, which scored airway obstruction and dysphagia on a 4-point scale (none, mild, moderate, severe/life-threatening); patients with severe/life-threatening airway obstruction and/or dysphagia based on this form were excluded. In RTOG 91-11, data on pre-treatment use of feeding tubes were not collected. In RTOG 97-03 and RTOG 99-14, pre-treatment feeding tube data were collected, and this was used as the primary means of defining patients with pre-treatment severe laryngopharynx dysfunction.
Patients with missing/inevaluable data or early death from acute toxicity were also excluded.
Statistical Analysis
Frequency tables with counts and percentages were used to describe pretreatment and treatment characteristics for each group. Univariate and multivariable logistic regression models were used to identify associations of pretreatment and treatment-related factors with severe late toxicity. All models were stratified by the 5 treatment arms described above. 
Results
The original, potential patient population from these three studies was 479. However, there were 130 patients excluded because of local-regional failure or death due to cancer, 100 patients excluded because of severe pre-treatment laryngopharynx dysfunction due to tumor, 13 patients excluded because of missing data, and 6 patients excluded because of early death due to acute toxicity (see Table 1 );. Thus, the overall evaluable sample size for this report was 230 patients. The median followup for the patient population is 2.96 years.
Of these 230 patients, 99 patients (cases) had severe late toxicity and 131 patients (controls) did not have severe late toxicity. This results in a crude rate of late toxicity of 43%. It should be noted that if the entire population of patients (N=479) from all three studies are analyzed (as is often performed for studies of late effects) the crude rate would appear to be 21%., considerably lower than the data reported here. An actuarial plot of "Time to Severe Late Toxicity" for all 230 evaluable patients is shown in Figure 1 . * Feeding tube data were not collected at all in RTOG 91-11. ** Numbers do not always add up along columns, due to some patients having more than one toxicity event.
The pre-treatment characteristics of these 230 patients are shown in Table  2 , including both pre-treatment and treatment-related characteristics. Table 3 shows an accounting of the types of late toxicity events observed in this analysis; most were related to swallowing function (particularly in RTOG 97-03 and RTOG 99-14) or laryngeal dysfunction (RTOG 91-11).
Patients with severe toxicities (cases) were more likely to be older and/or to have larger T-stage and/or larynx/hypopharynx primary cancer. On univariate analysis, there were no statistically significant differences in the rates of late effects based on each individual study/arm.
Univariate logistic regression analysis of pre-treatment and treatmentrelated variables is shown in Table 4 . Actuarial estimates of time to severe late toxicity as a function of T-stage, primary tumor site, and neck dissection are shown in Figures 2a to 2c , respectively. The most significant pre-treatment factor associated with severe late toxicity was age, analyzed as a continuous variable (p=0.0038) -older patients were significantly more likely to have severe late toxicity. T-stage (T3-4 more likely to have severe late toxicity) and tumor site (larynx/hypopharynx more likely to have severe late toxicity) were also statistically significant factors. On univariate analysis, none of the treatment-related variables were statistically significant except BED (p<0.0001), with a paradoxical negative association between BED and severe late toxicity. The p-value for potential association between severe late toxicity and neck dissection after RT was 0.145.
The results of a multivariable logistic regression model analysis are shown in Table 4 . Age, T-stage and tumor site remained statistically significant. In addition, a positive association between post-treatment neck dissection and severe late toxicity was noted (p=0.02). Specifically, out of the 230 patients in this study, 47 (20%) underwent post-treatment neck dissection; this included 22% of the oral cavity/oropharynx patients and 19% of the larynx/hypopharynx patients. These 47 patients had a Of note, besides neck dissection, other treatment-related factors were not associated with severe late effects. Although the most aggressive radiotherapy fractionation trial (RTOG 99-14, which used concomitant boost XRT + cisplatin) numerically had the highest crude rate of severe late toxicity (21/40 = 53%), there were no statistically significant differences among the trial arms.
As noted in Table 4 , radiotherapy dose delivered (as analyzed as biologically equivalent dose [BED]) was significant on univariate analysis (with a paradoxical relationship in which lower RT dose was associated with higher risk) but fell out of the multivariable model. The amount of chemotherapy delivered was not statistically significant in either model.
Discussion
This retrospective analysis of several prospective trials shows that the rate of severe late toxicity after CCRT for SCCHN is high, particularly with the analysis methodology used here. Specifically, in this study, patients with severe pre-treatment laryngopharynx dysfunction and patients with early tumor recurrence were excluded a priori from this analysis. Thus, the number of patients "at risk" for a severe late toxicity event is much smaller than the original treated population. This technique closely approximates the use of actuarial analysis of late complications, a technique which yields a higher rate of complications than simply reporting crude rate of complications, as reported by Bentzen et al. 20 A true actuarial analysis of late complications in head and neck cancer is difficult, because it is not easy to ascertain a date of onset of a late complication in any one individual patient (Figures 2a-2c ). Our sample size of 230 patients makes this one of the largest studies of late toxicity in the concurrent chemoradiotherapy era.
In this study, several factors that correlated with severe late toxicity were identified. Since this is a retrospective study, the data must be considered hypothesis-generating rather than definitive. Some caveats result from the fact that these studies were conducted over a 10-year time period (approximately 1991-2001) , with variations in eligibility, treatment, and data collection techniques. A second problem inherent to retrospective studies like ours is that a number of potentially important factors may not have been collected at all. For example our database does not include information on tumor volume, cardiopulmonary co-morbidity, and amount of tobacco consumed in followup.
However, it is logical to believe that age, tumor site and tumor stage would predict for greater likelihood of severe late toxicity. The finding that post-treatment neck dissection was significantly associated with severe late toxicity was somewhat more surprising, although this has been reported previously. The number of patients undergoing posttreatment neck dissection was relatively small (20%, despite over 50% of the patients having N2-3 disease), and thus these data can not be considered conclusive. It is possible that selection bias could lead to this association; for example, patients with larger volume neck disease may be more likely to undergo neck dissection and may be more likely to have neck-tumor-related damage to adjacent normal tissues unrelated to the neck dissection. It is possible, though, that disturbance of the soft tissues of the neck via post-treatment neck dissection could cause added swallowing dysfunction, for example by increasing fibrosis in the neck and thus limiting the mobility of the laryngopharynx. It should be noted that a similar report of an association between severe late toxicity and post-treatment neck dissection was recently reported by researchers at . If these findings are validated in additional, larger datasets, there may be important implications with respect to the controversy regarding neck dissection following chemoradiotherapy for patients with advanced neck disease.
The lack of significant association between cumulative radiotherapy dose delivery (or chemotherapy dose delivery) and severe late toxicity may be due to the narrow dose range prescribed and the generally excellent compliance. We are currently analyzing the detailed radiotherapy records (simulation films, dosimetry and treatment records) available at RTOG headquarters in order to estimate the doses received by individual normal tissue sub-structures within the head and neck. Several recent single-institution studies have rigorously analyzed the relationships between radiotherapy dose-volume-histograms for normal structures and the risk and severity of toxicities 22, 23 .
Considering the widespread acceptance of CCRT for SCCHN over the last 10 years, there are relatively few detailed studies of late toxicities. GORTEC reported long-term followup from their randomized trial of radiotherapy alone versus 5-FU/carboplatin/radiotherapy for oropharynx cancer; they did not find a significant difference in severe late toxicity 24 . However, there were fewer than 50 long-term survivors in that study. Staar reported that 51% of long-term survivors (> 2 years) after a very intense combination of accelerated fractionation radiotherapy and chemotherapy were dependent on feeding tubes 8 . With longer followup, that alarmingly high rate did decrease, and was not significantly worse than accelerated radiotherapy alone but the number of evaluable patients was relatively small These data suggest that the CCRT has reached the limits of acceptable long-term toxicity. Dose intensity can not be easily increased without some new and effective technique(s) of protection against late effects. In the future, these may include modern techniques in radiotherapy technology 27, 28 , or biopharmacologic radioprotectors [29] [30] [31] . Presently, however, these techniques have only succeeded in reducing xerostomia, not severe late dysphagia. Emphasis should therefore be on careful patient selection for aggressive treatment and swallowing exercises before during and after radiotherapy 32, 33 . Some patients may benefit from more invasive procedures, such as dilatation of hypopharyngeal/esophageal stricture under anesthesia.
For some patient subpopulations the risks of concurrent chemoradiotherapy may outweigh the benefits. For example, subgroup analysis of a meta-analysis suggested that there was no significant survival benefit to CCRT in patients older than age 70 1 . Our data may add to the controversy regarding management of the elderly patient with head and neck cancer -if there is no significant survival benefit and a significant increase in late toxicity with concurrent chemoradiotherapy, should it be the standard of care in this patient population?
Our study has several limitations that should be discussed. First, it is a "meta-analysis" of three separate clinical trials, each of which had somewhat different eligibility criteria, chemoradiotherapy regimen, and year of activation. However, all of the patients did receive treatment that would be considered appropriate standard of care in today's oncology clinic. Second, our exclusion of patients with pre-existing severe laryngopharynx dysfunction from this analysis can be considered controversial. Although patients were excluded a priori, determining pre-existing severe laryngopharynx dysfunction is subjective. However, it should be noted that the determination of post-treatment severe laryngopharynx dysfunction (toxicity) is also subjective. It is extremely difficult to determine if severe dysfunction after treatment is the result of treatment or the result of the pre-existing cancer. By excluding patients with pre-treatment severe laryngopharynx dysfunction, we attempted to isolate the influence of treatment on outcomes. Third, our study is an exploratory analysis; while it is one of the larger series on late toxicity after chemoradiotherapy, the number of patients and number of events are relatively small. We plan to address this in the future with an analysis of the recently completed trial, RTOG 0129. This was a randomized trial of standard fractionation versus accelerated fractionation radiotherapy (with cisplatin in both arms). Preliminary acute and subacute toxicity data showed no significant differences between the two arms 34 . It is premature at this time to perform a detailed analysis of efficacy or late toxicity from that study. It is possible that with improved knowledge and experience with CCRT and supportive care available in the 21 st century, outcomes may be improved in RTOG 0129 compared to historical controls.
Ultimately, it should be remembered that for most patients with head and neck cancer, the highest priority is cure and length of survival 35 .
Excessive concern about treatment toxicity should not prevent the use of proven aggressive multimodality treatment, provided the patient is well informed about the potential late sequelae of these aggressive treatment regimens.
